☆ 4.7 Editorial Material

Fecal Fixation: Fecal Microbiota Transplantation for Clostridium difficile Infection

CLINICAL INFECTIOUS DISEASES (2017)

期刊

CLINICAL INFECTIOUS DISEASES

卷 64, 期 3, 页码 272-274

出版社

OXFORD UNIV PRESS INC

DOI: 10.1093/cid/ciw735

关键词

fecal microbiota transplant; Clostridium difficile; CDI

类别

Immunology Infectious Diseases Microbiology

资金

US Department of Veterans Affairs Research Service

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Article Gastroenterology & Hepatology

Fecal Microbiota Transplant for Clostridioides Difficile Infection Is Safe and Efficacious in an Immunocompromised Cohort

Kelly Suchman, Yuying Luo, Ari Grinspan

Summary: This study supports the efficacy and safety of fecal microbiota transplant (FMT) for Clostridioides difficile infection (CDI) in immunocompromised patients. The primary cure rate was 85.1% and the overall cure rate was 86.5%. Serious adverse events were experienced by 11.7% of patients following FMT.

DIGESTIVE DISEASES AND SCIENCES (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Fecal Microbiota Transplantation and Medical Therapy for Clostridium difficile Infection Meta-analysis of Randomized Controlled Trials

Tanveer Singh, Prabhjot Bedi, Karandeep Bumrah, Darshan Gandhi, Tanureet Arora, Nikita Verma, Mary Schleicher, Manoj P. Rai, Rajat Garg, Beni Verma, Madhusudhan R. Sanaka

Summary: Fecal microbiota transplantation (FMT) is effective in the treatment of recurrent Clostridium difficile infection (CDI), but not significant in primary CDI.

JOURNAL OF CLINICAL GASTROENTEROLOGY (2022)

添加到收藏夹

Review Gastroenterology & Hepatology

Systematic Review with Meta-Analysis: Fecal Microbiota Transplantation for Severe or Fulminant Clostridioides difficile

Emily N. Tixier, Elijah Verheyen, Yuying Luo, Lauren Tal Grinspan, Charles H. Du, Ryan C. Ungaro, Samantha Walsh, Ari M. Grinspan

Summary: Fecal microbiota transplantation (FMT) shows potential efficacy in treating severe and fulminant Clostridioides difficile infection, although cure rates are modest and adverse events are significant.

DIGESTIVE DISEASES AND SCIENCES (2022)

添加到收藏夹

Article Microbiology

Intestinal microbiota changes pre- and post-fecal microbiota transplantation for treatment of recurrent Clostridioides difficile infection among Iranian patients with concurrent inflammatory bowel disease

Fahimeh Sadat Gholam-Mostafaei, Masoumeh Azimirad, Kaveh Naseri, Ali Nabavi-Rad, Hamid Asadzadeh Aghdaei, Shabnam Shahrokh, Nasser Ebrahimi Daryani, Abbas Yadegar, Mohammad Reza Zali

Summary: This study aimed to investigate the impact of fecal microbiota transplantation (FMT) on intestinal microbiota alterations in Iranian rCDI patients with underlying IBD. The results showed that the fecal microbiota profile of recipients became more similar to donor samples after the transplantation, with a significant increase in the relative abundance of Bacteroidetes. This study demonstrates that FMT is a safe and effective approach to restore the indigenous composition of the intestinal microbiota in rCDI patients and ultimately results in the treatment of concurrent IBD.

FRONTIERS IN MICROBIOLOGY (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Clinical effectiveness of bidirectional fecal microbiota transfer in the treatment of recurrent Clostridioides difficile infections

Christian Bestfater, Maria J. G. T. Vehreschild, Andreas Stallmach, Kester Tueffers, Andreas Erhardt, Thorsten Frank, Thomas Glueck, Felix Goeser, Gernot Sellge, Philipp Solbach, Herbert Eisenlohr, Martin Storr

Summary: Simultaneous bidirectional FMT showed superior primary cure rates compared to standard unidirectional approaches for recurrent Clostridioides difficile infection, highlighting the importance of treatment route in optimizing patient outcomes. Further prospective studies are needed to confirm these findings.

DIGESTIVE AND LIVER DISEASE (2021)

添加到收藏夹

Article Cell Biology

The Efficacy of Faecal Microbiota Transplant and Rectal Bacteriotherapy in Patients with Recurrent Clostridioides difficile Infection: A Retrospective Cohort Study

Camilla Kara Svensson, Frederik Cold, Iben Ribberholt, Mike Zangenberg, Hengameh Chloe Mirsepasi-Lauridsen, Andreas Munk Petersen, Morten Helms

Summary: This retrospective cohort study found that FMT capsules were more effective than FMT enema and RBT in treating recurrent CDI, and reduced the risk of further recurrences.

CELLS (2022)

添加到收藏夹

Article Immunology

Characterization of the gut microbiome of patients with Clostridioides difficile infection, patients with non-C. difficile diarrhea, and C. difficile-colonized patients

Silvia Vazquez-Cuesta, Laura Villar, Nuria Lozano Garcia, Ana I. Fernandez, Maria Olmedo, Luis Alcala, Mercedes Marin, Patricia Munoz, Emilio Bouza, Elena Reigadas

Summary: This study aimed to explore the role of the microbiome as a predictive biomarker of CDI. The researchers found differences in microbiome patterns between CDI patients, C. difficile carriers, healthy individuals, and patients with diarrhea of other causes, and identified potential microbiome biomarkers that could aid in the diagnosis of true CDI infections.

FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Changes in IgA-targeted microbiota following fecal transplantation for recurrent Clostridioides difficile infection

Kelsey E. Huus, Marcin Frankowski, Maja Pucic-Bakovic, Frano Vuckovic, Gordan Lauc, Benjamin H. Mullish, Julian R. Marchesi, Tanya M. Monaghan, Dina Kao, B. Brett Finlay

Summary: This study found that IgA-bacterial interactions are reestablished in human FMT recipients to resemble that of the healthy fecal donor. The data suggests that the IgA-bacterial interactions are influenced by the bacterial species and the fecal donor identity in the FMT recipients.

GUT MICROBES (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Clinical characteristics associated with the severity of Clostridium [Clostridioides] difficile infection in a tertiary teaching hospital from Mexico

Laura Tijerina-Rodriguez, Elvira Garza-Gonzalez, Adrian Martinez-Melendez, Rayo Morfin-Otero, Adrian Camacho-Ortiz, Esteban Gonzalez-Diaz, Hector Raul Perez-Gomez, Licet Villarreal-Trevino, Hector Maldonado-Garza, Sergio Esparza-Ahumada, Eduardo Rodriguez-Noriega

Summary: This study evaluated risk factors associated with severe-complicated and recurrent outcomes in different age groups of Clostridium difficile infection (CDI) patients. Female gender and lymphoma were identified as risk factors for severe-complicated CDI, while mature adulthood, previous rifampicin use, and neoplasm were risk factors for recurrent infection. Autoimmune disorders, leukemia, lymphoma, and previous colistin treatment were found to be risk factors for 30-day mortality.

BIOMEDICAL JOURNAL (2022)

添加到收藏夹

Review Medicine, General & Internal

Gut microbiota and microbiota-based therapies for Clostridioides difficile infection

Teena Chopra, Gail Hecht, Glenn Tillotson

Summary: Clostridioides difficile infection poses challenges due to its recurrent nature, and current antibiotic management does not address the underlying issue of dysbiosis. Restoring the microbiome through therapies like live biotherapeutics can lead to positive clinical outcomes. Several such therapies are currently being investigated.

FRONTIERS IN MEDICINE (2023)

添加到收藏夹

Article Public, Environmental & Occupational Health

Does Fecal Microbiota Transplant Have a Role in Treating Recurrent Clostridioides difficile Infection in Rural Hospitals?

Krishna Vedala, Philip Sobash, Parth Shah, Gilbert-Roy Kamoga

Summary: Clostridioides difficile infection imposes a significant economic burden in inpatient and rural settings. Fecal Microbiota Transplant, although limited by guidelines and resources, has been shown to save an average of $11,603.49 per patient after the first recurrence of CDI. Our study suggests that utilizing FMT in rural hospitals for recurrent CDI treatment could be economically beneficial.

FRONTIERS IN PUBLIC HEALTH (2021)

添加到收藏夹

Article Immunology

Management of Severe and Severe/Complicated Clostridoides difficile Infection Using Sequential Fecal Microbiota Transplant by Retention Enema

Abbas Hatim Rupawala, Darrel Gachette, Mena Bakhit, Lanre Jimoh, Colleen R. Kelly

Summary: The study found that serial fecal microbiota transplant may not always be effective in patients with severe or complicated Clostridoides difficile infection unresponsive to standard antibiotic therapy, and may lead to serious adverse events.

CLINICAL INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Biotechnology & Applied Microbiology

The evaluation of fecal microbiota transplantation vs vancomycin in a Clostridioides difficile infection model

Qiaomai Xu, Shumeng Zhang, Jiazheng Quan, Zhengjie Wu, Silan Gu, Yunbo Chen, Beiwen Zheng, Longxian Lv, Lanjuan Li

Summary: Vancomycin is the preferred treatment for CDI but has a high recurrence rate. FMT has emerged as a successful treatment for recurrent CDI. Our study suggests that FMT can better restore gut microbiota and metabolites, promoting the recovery of colonization resistance in mice compared to vancomycin.

APPLIED MICROBIOLOGY AND BIOTECHNOLOGY (2022)

添加到收藏夹

Article Infectious Diseases

Fecal Microbiota Transplantation May Be the Best Option in Treating Multiple Clostridioides difficile Infection: A Network Meta-Analysis

Fanni Dembrovszky, Noemi Gede, Zsolt Szakacs, Peter Hegyi, Szabolcs Kiss, Nelli Farkas, Zsolt Molnar, Marcell Imrei, Dora Dohos, Zoltan Peterfi

Summary: This network meta-analysis found that vancomycin + FMT may be the most effective option for the treatment and prevention of multiple recurrent CDI, while tolevamer and vancomycin + FMT seemed to be the most effective in preventing recurrence.

INFECTIOUS DISEASES AND THERAPY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Effect of antibiotic pretreatment on bacterial engraftment after Fecal Microbiota Transplant (FMT) in IBS-D

Prashant Singh, Eric J. Alm, John M. Kelley, Vivian Cheng, Mark Smith, Zain Kassam, Judy Nee, Johanna Iturrino, Anthony Lembo

Summary: Fecal microbiota transplantation is an effective strategy to correct microbial dysbiosis in diarrhea-predominant irritable bowel syndrome. For patients with IBS-D, FMT with antibiotic pretreatment significantly reduces bacterial engraftment.

GUT MICROBES (2022)

添加到收藏夹

Review Public, Environmental & Occupational Health

Perils and pitfalls of probiotic quasi-experimental studies for primary prevention of Clostridioides difficile infection: A review of the evidence

Lynne McFarland, Stuart B. Johnson, Charlesnika T. Evans

Summary: The review examined quasi-experimental studies adding probiotics to infection control protocols to reduce CDI rates, finding that certain probiotics showed promise in reducing infections. However, the study design was influenced by various factors that must be carefully considered.

AMERICAN JOURNAL OF INFECTION CONTROL (2021)

添加到收藏夹

Article Microbiology

Epidemiologic trends in Clostridioides difficile isolate ribotypes in United States from 2011 to 2016

D. R. Snydman, L. A. McDermott, S. G. Jenkins, E. J. C. Goldstein, R. Patel, B. A. Forbes, S. Johnson, D. N. Gerding, C. M. Thorpe, S. T. Walk

ANAEROBE (2020)

添加到收藏夹

Article Immunology

Efficacy of Bezlotoxumab in Trial Participants Infected With Clostridioides difficile Strain BI Associated With Poor Outcomes

Stuart Johnson, Diane M. Citron, Dale N. Gerding, Mark H. Wilcox, Ellie J. C. Goldstein, Susan P. Sambol, Emma L. Best, Karen Eves, Erin Jensen, Mary Beth Dorr

Summary: In the MODIFY I/II trials, infection with BI strains of C. difficile was associated with poor outcomes. Bezlotoxumab treatment was effective in both BI and non-BI subpopulations.

CLINICAL INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Public, Environmental & Occupational Health

Sequential introduction of a multistep testing algorithm and nucleic acid amplification testing leading to an increase inClostridioides difficiledetection and a trend toward increased strain diversity

Andrew M. Skinner, Brian Yu, Adam Cheknis, Susan M. Pacheco, Dale N. Gerding, Stuart Johnson

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

The Relative Role of Toxins A and B in the Virulence of Clotridioides difficile

Andrew M. Skinner, S. Tyler Phillips, Michelle M. Merrigan, Kevin J. O'Leary, Susan P. Sambol, Farida Siddiqui, Lance R. Peterson, Dale N. Gerding, Stuart Johnson

Summary: Most pathogenic strains of C. difficile possess two large molecular weight single unit toxins that disrupt the actin cytoskeleton of intestinal epithelial cells, leading to diarrhea. While TcdB alone can cause disease, TcdA-/TcdB+ mutant strains have been shown to be responsible for C. difficile infection, which are typically mild in nature.

JOURNAL OF CLINICAL MEDICINE (2021)

添加到收藏夹

Article Immunology

A Tapered-pulsed Fidaxomicin Regimen Following Treatment in Patients With Multiple Clostridioides difficile Infection Recurrences

Andrew M. Skinner, Xing Tan, Benjamin D. Sirbu, Larry H. Danziger, Dale N. Gerding, Stuart Johnson

Summary: The tapered-pulsed fidaxomicin regimen shows promising results in managing multiple recurrent Clostridioides difficile infections (mrCDI), with sustained clinical response rates of 74% at 30 days and 61% at 90 days.

CLINICAL INFECTIOUS DISEASES (2021)

添加到收藏夹

Review Infectious Diseases

Potential Roles for Probiotics in the Treatment of COVID-19 Patients and Prevention of Complications Associated with Increased Antibiotic Use

Ravina Kullar, Stuart Johnson, Lynne V. McFarland, Ellie J. C. Goldstein

Summary: Medical care for hospitalized COVID-19 patients is constantly evolving, with a majority receiving empiric antibiotics which can lead to antibiotic-related diarrhea. Strategies such as antimicrobial stewardship programs and specific probiotic strains have shown promise in reducing these adverse effects and are currently being studied in trials for COVID-19 patients.

ANTIBIOTICS-BASEL (2021)

添加到收藏夹

Article Immunology

Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults

Stuart Johnson, Valery Lavergne, Andrew M. Skinner, Anne J. Gonzales-Luna, Kevin W. Garey, Ciaran P. Kelly, Mark H. Wilcox

Summary: This guideline offers focused updates on the management of Clostridioides difficile infection (CDI) in adults, specifically addressing the use of fidaxomicin and bezlotoxumab. Recommendations are based on evidence from systematic literature reviews and rated using the GRADE approach.

CLINICAL INFECTIOUS DISEASES (2021)

添加到收藏夹

Letter Gastroenterology & Hepatology

Why Do ACG and AGA Guidelines Differ for the Use of Probiotics and the Prevention of CDI?

Lynne V. McFarland, Ravina Kullar, Stuart Johnson, Jason C. Sniffen, Kristin Woolard, Ellie J. C. Goldstein

AMERICAN JOURNAL OF GASTROENTEROLOGY (2022)

添加到收藏夹

Article Infectious Diseases

Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial

Robert Orenstein, Erik R. Dubberke, Sahil Khanna, Christine H. Lee, David Yoho, Stuart Johnson, Gail Hecht, Herbert L. DuPont, Dale N. Gerding, Ken F. Blount, Sarah Mische, Adam Harvey

Summary: In this Phase 2 trial, RBX2660 was found to be safe and effective in reducing the recurrence of rCDI compared to a historical control group. Microbiome changes in participants treated with RBX2660 were consistent with protective changes against C. difficile recurrence.

BMC INFECTIOUS DISEASES (2022)

添加到收藏夹

Letter Immunology

Can Clostridium innocuum Masquerade as Clostridioides difficile?

Andrew M. Skinner, Laurica Petrella, Stacey Spandoni, Fidel Serna-Perez, Stuart Johnson

CLINICAL INFECTIOUS DISEASES (2022)

添加到收藏夹

Article Medicine, Research & Experimental

Defining optimal treatment for recurrent Clostridioides difficile infection (OpTION study): A randomized, double-blind comparison of three antibiotic regimens for patients with a first or second recurrence

Stuart Johnson, Dale N. Gerding, Xue Li, Domenic J. Reda, Curtis J. Donskey, Kalpana Gupta, Matthew Bidwell Goetz, Michael W. Climo, Fred M. Gordin, Robert Ringer, Neil Johnson, Michelle Johnson, Lawrence A. Calais, Alexa M. Goldberg, Ling Ge, Tamara Haegerich

Summary: This study aims to compare three antibiotic treatments for patients with recurrent CDI and determine the optimal treatment. The study is designed as a prospective, double-blind, multi-center clinical trial, and includes protocol modifications based on early trial experience and clinical realities.

CONTEMPORARY CLINICAL TRIALS (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Absence of toxin gene transfer from Clostridioides difficile strain 630Δerm to nontoxigenic C. difficile strain NTCD-M3r in filter mating experiments

Susan P. Sambol, Stuart Johnson, Adam Cheknis, Dale N. Gerding

Summary: This study successfully transferred the pathogenicity locus (PaLoc) from toxigenic Clostridioides difficile strain to a nontoxigenic strain CD37 but not to the nontoxigenic strain NTCD-M3r. This finding provides important insights into the mechanism of toxin transfer in Clostridioides difficile.

PLOS ONE (2022)

添加到收藏夹

Article Infectious Diseases

Antimicrobial susceptibility of Clostridioides difficile to omadacycline and comparator antimicrobials

Andrew M. Skinner, Laurica A. Petrella, Adam Cheknis, Stuart Johnson

Summary: Omadacycline has demonstrated a high level of activity towards C. difficile compared to commonly used antimicrobials for CABP and ABSSSI. The study results show that there were no notable elevations in the in vitro omadacycline MIC among contemporary C. difficile isolates.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2023)

添加到收藏夹

Article Microbiology

Effective Colonization by Nontoxigenic Clostridioides difficile REA Strain M3 (NTCD-M3) Spores following Treatment with Either Fidaxomicin or Vancomycin

Susan P. Sambol, Andrew M. Skinner, Fidel Serna-Perez, Benjamin Owen, Dale N. Gerding, Stuart Johnson

Summary: This study aimed to investigate the colonization of NTCD-M3 after treatment with fidaxomicin, an alternative antibiotic to vancomycin, in a hamster model of C. difficile infection (CDI). The results showed that NTCD-M3 successfully colonized all hamsters treated with fidaxomicin, similar to those treated with vancomycin. The presence of high levels of OP-1118 and vancomycin in feces during treatment suggests the potential effectiveness of NTCD-M3 for preventing recurrent CDI.

MICROBIOLOGY SPECTRUM (2023)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.